Plasma Fractionation Market Overview:
The global plasma fractionation market was valued at $18,222 million in 2019, and is expected to reach $23,006 million by 2027, registering a CAGR of 6.2% from 2020 to 2027.
Fractionation is a process carried out to separate certain quantity of a mixture. Furthermore, plasma is the fluid component of blood, which is fractionated to obtain different plasma derivatives such as albumin and immunoglobulins. These derived plasma products have therapeutic effects and are employed in the treatment of various blood plasma related disorders. For instance, coagulation factor VIII is a plasma derivative, which is used for treatment and prophylaxis of hemophilia. Furthermore, it is also employed to stop excessive blood loss during surgical procedures. Similarly, immunoglobulins are employed in the treatment of primary and secondary immune deficiencies.
Surge in geriatric population across the globe, which is predisposed to various rare diseases that require use of plasma derivatives is the major factor that boosts the plasma fractionation market growth.
Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuels the growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward the growth of the market. In addition, favorable government support to spread awareness related to use of plasma derived products also propels the growth of the plasma fractionation market. However, high cost of plasma derived products restricts growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.
COVID-19 pandemic has affected every industry worldwide. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This leads to disruption, limitation, challenges, and changes in each sector of every industry. Similarly, the plasma fractionation industry was also impacted by the pandemic. For instance, the outbreak of COVID-19 pandemic has led to decrease in number of blood donations and plasma collections, which hampers the market growth as it leads to shortage in raw material supply. However, decrease in raw material supply was compensated by fall in demand for plasma derivatives in the starting of nationwide lockdowns, as elective surgical procedures were postponed and availability of treatment for other medical conditions was also hampered. In addition, overall plasma supply in countries is maintained, however, some areas may face shortages. Thus, the viral outbreak had a negative impact on the plasma fractionation market.
Plasma Fractionation Market Segmentation
The global plasma fractionation market is segmented on the basis of product, sector, and region. On the basis of product, the market is divided into albumin, immunoglobulins, coagulation factor VIII, and coagulation factor IX. By sector, the market is bifurcated into public sector and private sector. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Product
Immunoglobulin segment is projected as one of the most lucrative segment.
Segment review
In terms of value, by product, immunoglobulin is the largest segment in the plasma fractionation market and is also expected to exhibit the fastest growth rate during the forecast period. The growth of this segment is attributable to diversified use of immunoglobulin in various disorders such as primary and secondary immune deficiencies, autoimmune diseases, and inflammatory diseases. Furthermore, surge in research related to immunology across the globe is another factor that contributes toward the growth of the immunoglobulin market.
In terms of value, by sector, the private sector acquired largest plasma fractionation market share during the forecast period. This is attributable to the fact that there are a large number of private players operating in the plasma fractionation industry, who collect and fractionate large amount of plasma into derivatives such as albumin and immunoglobulin. Thus, contribute toward plasma fractionation marker growth.
By Sector
Private Sector segment held a dominant position in 2019 and will continue to maintain the lead over the forecast period.
Snapshot of Asia-Pacific plasma fractionation market
Asia-Pacific presents lucrative opportunities for key players operating in the plasma fractionation market, owing to presence of governmental bodies that regulate and supervise plasma collection, fractionation, and sales is the major factor that boosts the market growth. In addition, surge incidences of medical conditions such as severe fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary & secondary immune deficiencies also fuel the growth of the market. Furthermore, increase in geriatric population, rise in government support through Medicaid and healthcare policies, and developments in the healthcare infrastructure are other factors that drive the growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the plasma fractionation market in the region.
The key players profiled in this report include Baxter International Inc., Bio product laboratory, Biotest AG, CSL Ltd., Grifols SA, Kedrion S.P.A (Kedrion Biopharma Inc.), LFB S. A., Octapharma AG, Sanquin Blood Supply Foundation, and Takeda Pharmaceutical Company Limited.
By Region
Asia-Pacific would exhibit the highest CAGR of 6.6% during 2020-2027.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the plasma fractionation market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers plasma fractionation market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global plasma fractionation market growth.
Key Market Segments
By Product
- Albumin
- Immunoglobulins
- Coagulation factor VIII
- Coagulation factor IX
By Sector
- Public Sector
- Private Sector
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Turkey
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Taiwan
- South Korea
- Indonesia
- Thailand
- Malaysia
- Vietnam
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Kingdom of Saudi Arabia
- Rest of LAMEA
Plasma Fractionation Market Report Highlights
| Aspects | Details |
 By PRODUCT |
|
 By SECTOR |
|
 By Region |
|
 Key Market Players | SANQUIN BLOOD SUPPLY FOUNDATION, CSL LTD., OCTAPHARMA AG, TAKEDA PHARMACEUTICAL COMPANY LIMITED, BAXTER INTERNATIONAL INC., KEDRION S.P.A. (KEDRION BIOPHARMA INC.), LFB S. A, BIO PRODUCTS LABORATORY, BIOTEST AG, GRIFOLS SA |
Analyst Review
Plasma fractionation products are expected to witness high adoption in the future, owing to increase in number of plasma collection centers. In addition, the market exhibits high growth rate, owing to surge in awareness about use of plasma fractionation products in various medical aspects. Moreover, surge in geriatric population across the globe, which is predisposed to rare diseases that require plasma products for treatment also fuels growth of the market. North America and Asia-Pacific are expected to offer lucrative growth opportunities to key players. This is majorly attributed to factors such as improvement in healthcare facilities, rise in disposable income, and rapid improvement in economic conditions. However, high cost of plasma products hinders growth of the plasma fractionation market. Plasma fractionation product manufacturers and distributors have focused on expansion of their presence in emerging economies to strengthen their foothold in the market.
The total market value of plasma fractionation market is $18,222 million in 2019.
The forecast period for plasma fractionation market is 2020 to 2027
The market value of plasma fractionation market in 2019 is $15,073 million.
The base year is 2019 in plasma fractionation market
Top companies such as, CSL Limited, Grifols SA, Takeda Pharmaceutical Company Limited, Baxter International Inc. and Octapharma AG dominated the market in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
Albumin segment is the most influencing segment as it is used in various medical conditions such as acute liver failure, cardiopulmonary bypass and others. Furthermore, it is also used in liver failure.
The major factor that fuels the growth of the global plasma fractionation market includes surge in prevalence of rare diseases across the globe which leads to rise in demand for plasma fractionation products
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 6.7%. This is due to presence of governmental bodies that regulate and supervise plasma collection, fractionation, and sales is the major factor that boosts the market growth. In addition, surge incidences of medical conditions such as severe fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary & secondary immune deficiencies also fuel the growth of the market.
Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of blood which is yellowish and holds blood cells
Plasma derived products are known as plasma derivatives obtained from fractionation. These products are used in various medical fields such as in neurology, hematology, critical care, and immunology. For instance, in critical care, plasma is prescribed to prevent and stop bleeding
Loading Table Of Content...
